Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Non-Valvular Atrial Fibrillation (From ROCKET AF)

The safety of intravenous thrombolysis in patients taking rivaroxaban has not been well established. We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the ROCKET AF trial. Review of medical and adverse event records for patients receiving thrombolytic therapy while enrolled in ROCKET AF was performed to determine their baseline characteristics, indications for thrombolysis, and type of agent used. Safety endpoints were 30-day post-thrombolytic rates of stroke, bleeding, and mortality.

Source: The American Journal of Cardiology - August 7, 2017 Category: Cardiology Authors: Sean T Chen, Anne S Hellkamp, Richard C Becker, Scott D Berkowitz, G ünter Breithardt, Keith AA Fox, Werner Hacke, Jonathan L Halperin, Graeme J Hankey, Kenneth W Mahaffey, Christopher C Nessel, Jonathan P Piccini, Daniel E Singer, Manesh R Patel Source Type: research